Biocartis Group NV Logo

Biocartis Group NV

ISIN: BE0974281132 | Ticker: BCART | LEI: 549300J4HOJL5KG8HY54

About Biocartis Group NV

Company Description

Biocartis is an innovative molecular diagnostics company committed to revolutionize molecular testing with its unique proprietary IdyllaTM platform. We provide next generation diagnostic solutions, aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus in oncology which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for COVID-19, flu, RSV and sepsis.

Biocartisโ€™ proprietary molecular diagnostics (MDx) IdyllaTM platform is a fully automated sample-to-result, real-time PCR system that offers accurate, highly reliable molecular information from virtually any biological sample, in virtually any setting, allowing fast and effective treatment selection and treatment progress monitoring.

Year founded


Served area





Generaal De Wittelaan 11B, 2800 Mechelen, Antwerpen โ€“ Belgium

Filings & Publications


Report Q1 H1 Q3 FY
Consolidated Report NLD
Corporate Governance Report
Company Presentation
General Presentation
Sustainability Report
Remuneration Report

Shareholder information

Shares outstanding



April 27, 2015

Stock exchange(s)

Euronext Brussels



Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.